Accountability of the pharmaceutical industry

Lancet

Volumn 360, Issue 9346, 2002, Pages 1682-1684

  Dukes, M N Graham ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; PRIORITY JOURNAL; PUBLIC HEALTH; SHORT SURVEY;

EID: 0037164322     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11599-6     Document Type: Review

References (27)

1. Richter J. Holding corporations accountable. 2001;Zed Books, London.
2. UN Sub-Commission on the Prevention of Discrimination and Protection of Minorities. 1998 Resolution Calling for the Establishment of a Working Group on the Working Methods and Activities of Transnational Corporations under the auspices of the UN Sub-Commission on the Protection and Promotion of Human Rights. Geneva: UN, 1998.
3. Pécoul B., Chirac P., Trouillier P., Pinel J. Access to essential drugs in poor countries: a lost battle? JAMA. 281:1999;361-367.
4. Trouillier P., Olliaro P.L. Drug development output: what proportion for tropical diseases? Lancet. 354:1999;164.
5. McNeil DG. Drug makers and 3rd World: study in neglect. New York Times, May 21, 2000: 1 and 6.
6. Boseley S. Third world dying for new medicines: drug giants wage war on impotence and obesity but neglect killer tropical diseases. The Guardian, Oct 10, 2001: 18.
7. Eaton L. Drug companies neglect research into diseases affecting the poor. BMJ. 323:2001;827.
8. Statistics on pharmaceutical services in the Netherlands, 2000-2001. Utrecht: GIP, 2002.
9. Guyatt G., Yalnizyan A., Devereaux P.J. Solving the public health care sustainability puzzle. CMAJ. 167:2002;36-37.
10. MSF. Why Drug Donations Won't Solve the Access Crisis: The Case of Fluconazole - A Matter of Life and Death. Geneva: MSF, 2001: 3.
11. Children's Vaccine Initiative (CAI). CAI forum, June, 1966.
12. Saunders C. Differential pricing: UNFPA's experience with contraceptives. Presented at the WHO/WTO Secretariat Workshop on Differential Pricing and Financing of Essential Drugs; Høsbjør, Norway; April 8-11, 2001. Available at http://www.who.int/medicines/library/edm_general/who-wto-hosbjor/ 17saunders_e.ppt (accessed Oct 7, 2002).
13. Mossialias E., Dukes M.N.G. Affordably priced new drugs for poor populations: proposal for a global solution. Int J Risk Safety Med. 14:2001;1-29.
14. Teixeira PR. Universal access to antiretroviral therapy: the Brazilian experience. Presented at the WHO/WTO workshop on differential pricing and financing of essential drugs; Høsbjør, Norway, April 8-11, 2001. Available at http://www.who.int/medicines/library/edm_general/who-wto-hosbjor/ 09Texeira_e.ppt (accessed Oct 4, 2002).
15. Summary Report of the WHO/WTO Secretariat Workshop Differential Pricing and Financing of Essential Drugs; Høsbjør, Norway; April 8-11, 2001. Geneva: WHO, 2001.
16. Laing RD. Health and pharmacy systems in developing countries. Presented at the WHO/WTO Secretariat Workshop on Differential Pricing and Financing of Essential Drugs; Høsbjør, Norway; April 8-11, 2001. Geneva: WHO, 2001.
17. Cragg G.M., Simon J.E., Jato J.G., Snader K.M. Drug discovery and development at the National Cancer Institute: potential for new pharmaceutical crops. Janick J. Progress in new crops. 1996;554-560 ASHS Press, Arlington.
18. Marsh P. Prescribing all the way to the bank. New Scientist, Nov 18, 1989.
19. Dukes M.N.G. The effects of drug regulation. 1985;WHO, Regional Office for Europe, Copenhagen.
20. Abraham J., Lewis G. Regulating medicines in Europe. 2000;Routledge, London.
21. Anon. Too many me-toos in EC. Scrip 1997; 2287: 2.
22. Hodgkin C. Harmonizing drug policy: making rules for tomorrow's market. HAI-lights. 1:1996;2-3.
23. General Accounting Office (USA). FDA Drug Review: Post-approval Risks 1976-85. Washington: General Accounting Office, 1990.
24. Horton R. WHO: the casualties and compromises of renewal. Lancet. 359:2002;1605-1611.
25. CPTech. South Africa. http://www.cptech.org/ip/health/sa/ (accessed Oct 4, 2002).
26. MSF. Prescriptions for Action. Brussels: MSF, 2001.
27. MSF. A Matter of Life and Death. Geneva: MSF, November, 2001.